Table 2 PS-weighted cause-specific Cox proportional hazard regression to estimate hazard ratio for renal function deterioration or improvement by baseline CKD stage using allopurinol as reference
Hazard ratio (95% CI) | ||
|---|---|---|
Renal function deterioration | Renal function improvement | |
Entire cohort | – | – |
Type of ULD | ||
Allopurinol | Reference | Reference |
Febuxostat | 1.77 (0.85–1.76) | 1.43 (1.26–1.62)* |
Uricosuric agents | 1.37 (0.71–1.37) | 1.00 (0.88–1.14) |
eGFR ≥ 90 | ||
Allopurinol | Reference | – |
Febuxostat | 1.97 (0.95–4.08) | – |
Uricosuric agents | 0.91 (0.48–1.70) | – |
eGFR 60–89 | ||
Allopurinol | Reference | Reference |
Febuxostat | 1.49 (0.74–3.02) | 1.88 (1.44–2.45)* |
Uricosuric agents | 1.15 (0.63–2.08) | 1.33 (1.02–1.72)* |
eGFR 30–59 | ||
Allopurinol | Reference | Reference |
Febuxostat | 0.96 (0.53–1.74) | 1.12 (0.84–1.49) |
Uricosuric agents | 0.93 (0.52–1.67) | 0.95 (0.72–1.26) |
eGFR 15–29 | ||
Allopurinol | Reference | Reference |
Febuxostat | 1.49 (0.43–5.15) | 1.32 (0.80–2.20) |
Uricosuric agents | 1.39 (0.40–4.82) | 1.46 (0.88–2.42) |